SEC Info
uses JavaScript!
To view pages properly, enable JavaScript in your browser.
SEC Info
℠
Home
Search
My Interests
Help
Sign In
Please
Sign In
Cencora, Inc.
PA
SEC # 1140859
118 Related Registrants:
More than a Year ago:
Ambulatory Pharmaceutical Services, Inc. — 7/18/12 — SEC # 1352093
Amerisource Health Services Corp. — 7/18/12 — SEC # 1161221
Amerisource Heritage Corp. — 7/18/12 — SEC # 1161222
AmerisourceBergen Consulting Services, Inc. — 7/18/12 — SEC # 1506265
AmerisourceBergen Drug Corp. — 7/18/12 — SEC # 1476003
AmerisourceBergen Holding Corp. — 7/18/12 — SEC # 1352092
AmerisourceBergen Services Corp. — 7/18/12 — SEC # 1476002
AmerisourceBergen Specialty Group, Inc. — 7/18/12 — SEC # 1476001
Anderson Packaging, Inc. — 7/18/12 — SEC # 1352091
APS Enterprises Holding Co., Inc. — 7/18/12 — SEC # 1352089
Asd Specialty Healthcare Inc. — 7/18/12 — SEC # 1161205
Automed Technologies Inc. — 7/18/12 — SEC # 1219011
Bellco Drug Corp. — 7/18/12 — SEC # 1476000
Clinical Outcomes Resource Application Corp. — 7/18/12 — SEC # 1476061
Dialysis Purchasing Alliance, Inc. — 7/18/12 — SEC # 1475999
Health Services Capital Corp. — 7/18/12 — SEC # 1161226
I.g.G. of America, Inc. — 7/18/12 — SEC # 1475998
IHS Acquisition XXX, Inc. — 7/18/12 — SEC # 1352088
Imedex, Inc. — 7/18/12 — SEC # 1352087
Integrated Commercialization Solutions Inc./CA — 7/18/12 — SEC # 1062258
International Oncology Network Solutions, Inc. — 7/18/12 — SEC # 1506264
International Physician Networks, L.L.C. — 7/18/12 — SEC # 1475997
IntrinsiQ Holdings, Inc. — 7/18/12 — SEC # 1533660
IntrinsiQ, LLC — 7/18/12 — SEC # 1533662
Lash Group Inc. — 7/18/12 — SEC # 1161219
Liberty Acquisition Corp. — 7/18/12 — SEC # 1476007
Medical Initiatives Inc. — 7/18/12 — SEC # 1161198
Pharm Plus Acquisition, Inc. — 7/18/12 — SEC # 1352095
Pharmacy Healthcare Solutions Ltd. — 7/18/12 — SEC # 1161228
Premier Source, LLC — 7/18/12 — SEC # 1533664
Solana Beach, Inc. — 7/18/12 — SEC # 1352523
Specialty Pharmacy of California, Inc. — 7/18/12 — SEC # 1352520
Specialty Pharmacy, Inc. — 7/18/12 — SEC # 1352519
Telepharmacy Solutions Inc. — 7/18/12 — SEC # 1130289
US Bioservices Corp. — 7/18/12 — SEC # 1352099
Value Apothecaries Inc. — 7/18/12 — SEC # 1161230
Xcenda, LLC — 7/18/12 — SEC # 1475996
Premier Source Diagnostics, Inc. — 11/9/11 — SEC # 1533671
Amerisource Corp./DE — 6/12/06 — SEC # 1161305
Amerisource Health Corp./DE — 6/12/06 — SEC # 855042
Amerisource Sales Corp. — 6/12/06 — SEC # 1161223
Brownstone Pharmacy Inc. — 6/12/06 — SEC # 1003756
Capstone Med Inc. — 6/12/06 — SEC # 1161502
Capstone Pharmacy of Delaware Inc. — 6/12/06 — SEC # 1161181
CliniCare Concepts, Inc. — 6/12/06 — SEC # 1352524
Compuscript Inc. — 6/12/06 — SEC # 1161193
Computran Systems Inc. — 6/12/06 — SEC # 872412
Dunnington RX Services of Massachusetts Inc. — 6/12/06 — SEC # 1003762
Dunnington RX Services of Rhode Island Inc. — 6/12/06 — SEC # 1003761
Express Pharmacy Services Inc. — 6/12/06 — SEC # 1161177
Family Center Pharmacy Inc. — 6/12/06 — SEC # 1161184
Goot Nursing Home Pharmacy Inc. — 6/12/06 — SEC # 1161190
Insta Care Pharmacy Services Corp. — 6/12/06 — SEC # 1003716
Ion LLC — 6/12/06 — SEC # 1219009
Leading Educational Research Network, LLC — 6/12/06 — SEC # 1363968
Network for Medical Communication & Research, LLC — 6/12/06 — SEC # 1363969
NMCR Holdings Inc. — 6/12/06 — SEC # 1363967
Pharmacy Corp. of America Inc. — 6/12/06 — SEC # 355531
Pharmacy Corp. of America Massachusetts Inc. — 6/12/06 — SEC # 1161213
Pharmerica Drug Systems Inc. — 6/12/06 — SEC # 1161214
Pharmerica Inc. — 6/12/06 — SEC # 792932
PMSI, Inc. — 6/12/06 — SEC # 1352096
Premier Pharmacy Inc. — 6/12/06 — SEC # 1161215
Reimbursement Education Network, LLC — 6/12/06 — SEC # 1352521
Rombros Drug Center Inc. — 6/12/06 — SEC # 1161211
RxFirst, Inc. — 6/12/06 — SEC # 1352522
Southwest Pharmacies, Inc. — 6/12/06 — SEC # 1352518
Taylor & Manno Asset Recovery, Inc. — 6/12/06 — SEC # 1352100
Tmesys Inc. — 6/12/06 — SEC # 1161217
Brudnick James Co. Inc. — 2/14/03 — SEC # 1161227
Medidyne Corp. — 2/14/03 — SEC # 1161220
Southwest Pharmaceuticals Inc. — 2/14/03 — SEC # 1161212
Allen Co. — 10/30/01 — SEC # 1161218
Alliance Health Services Inc. — 10/30/01 — SEC # 1003735
Alliance Home Health Care Inc. — 10/30/01 — SEC # 1003738
Asd Hemophilia Management LLC — 10/30/01 — SEC # 1161204
Asd Hemophilia Program LP — 10/30/01 — SEC # 1161203
BBC Laboratories — 10/30/01 — SEC # 1161206
BBC Operating Sub Inc. — 10/30/01 — SEC # 1161178
BBC Packing Corp. — 10/30/01 — SEC # 1161207
BBC Special Packaging Inc. — 10/30/01 — SEC # 1161208
BBC Transportation Co. — 10/30/01 — SEC # 1161209
Bergen Brunswig Corp. — 10/30/01 — SEC # 11454
Bergen Brunswig Drug Co. — 10/30/01 — SEC # 1161202
Bergen Brunswig Realty Services Inc. — 10/30/01 — SEC # 1161176
Beverly Acquisition Corp. — 10/30/01 — SEC # 1003691
CD Smith Healthcare Inc. — 10/30/01 — SEC # 1161224
Century Advertising Inc. — 10/30/01 — SEC # 1161187
Choice Medical Inc. — 10/30/01 — SEC # 1161191
Corrections Pharmacies Licensing Co. LLC — 10/30/01 — SEC # 1161182
Corrections Pharmacies LLC — 10/30/01 — SEC # 1161179
Corrections Pharmacies of California LP — 10/30/01 — SEC # 1161196
Corrections Pharmacies of Hawaii LP — 10/30/01 — SEC # 1161180
DD Wholesale Inc. — 10/30/01 — SEC # 1003759
Drug Service Inc. — 10/30/01 — SEC # 1161185
Dunnington Drug Inc. — 10/30/01 — SEC # 1003760
Durr Fillauer Medical Inc. — 10/30/01 — SEC # 30645
General Drug Co. — 10/30/01 — SEC # 1161225
Goot Westbridge Pharmacy Inc. — 10/30/01 — SEC # 1161194
Goots Goodies Inc. — 10/30/01 — SEC # 1161197
Goots Pharmacy & Orthopedic Supply Inc. — 10/30/01 — SEC # 1161199
Green Barn Inc. — 10/30/01 — SEC # 1161200
Healthcare Prescription Service Inc. — 10/30/01 — SEC # 1003692
Home Medical Equipment Health Co. — 10/30/01 — SEC # 1161201
Insta Care Holdings Inc. — 10/30/01 — SEC # 1003708
Inteplex Inc. — 10/30/01 — SEC # 1161183
KS Instrument Corp. — 10/30/01 — SEC # 1161186
Lad Drug Corp. — 10/30/01 — SEC # 1161188
Los Angeles Drug Corp. — 10/30/01 — SEC # 1161189
Management Systems of America Inc. — 10/30/01 — SEC # 1161195
MDP Properties Inc. — 10/30/01 — SEC # 1161192
Medical Health Industries Inc. — 10/30/01 — SEC # 64596
Omni Med B Inc. — 10/30/01 — SEC # 1003659
Pharmacy Dynamics Group Inc. — 10/30/01 — SEC # 1003663
Rightpak Inc. — 10/30/01 — SEC # 1161210
SBS Pharmaceuticals Inc. — 10/30/01 — SEC # 1161229
Southwestern Drug Corp./DE — 10/30/01 — SEC # 92484
Stadt Solutions LLC — 10/30/01 — SEC # 1161216
Click to view...
Registrant
About
Filings
Files
Relationships
Names
Topics
Web
345 Topics
within the
Past Year
Past Two Years
Past Three Years
Past Four Years
Past Five Years
Entire Database
Show:
Most-Recent Document
All Documents
And:
Exhibits
As Of
Filing
Doc.
Page
Title
Docs.
1/29/24
DEF 14A
1
A-1
2
2/6/24
424B2
1
About This Prospectus
4
1
About This Prospectus Supplement
4
1/29/24
DEF 14A
1
Advisory vote to approve the compensation of our named executive officers
2
2/6/24
424B2
1
Amerisourcebergen Corporation
4
5/2/23
10-Q
1
And 20
1
1
And 202
1
1
And September 30, 2022
1
1
And Six
1
1/29/24
DEF 14A
1
Appendix A
2
1
Approval of an amendment of the certificate of incorporation to provide for the exculpation of officers as permitted by Delaware law
2
1
Approval of miscellaneous amendments to the certificate of incorporation
2
5/2/23
10-Q
1
Arch
1
1/29/24
DEF 14A
1
Audit and non-audit fees
2
1
Audit matters
2
1
Availability of the Annual Report on Form 10-K
2
1
B-1
2
1
Board and governance matters
2
2/6/24
424B2
1
Capitalization
2
1
Cautionary Note Regarding Forward-Looking Statements
4
8/7/23
424B7
1
Cautionary Notice Regarding Forward-Looking Statements
2
2/6/24
424B2
1
Cautionary Statement Regarding Forward-Looking Information
2
1/29/24
DEF 14A
1
CEO pay ratio
2
8/7/23
424B7
1
Certain United States Federal Income Tax Consequences to Non-U.S. Holders
2
1/29/24
DEF 14A
1
Company highlights
2
1
Compensation discussion and analysis
2
8/2/23
10-Q
1
Consolidated Balance Sheets as of
2
1/31/24
10-Q
1
Consolidated Balance Sheets as of December 31, 2023 and September 30, 2023
1
11/21/23
10-K
1
Consolidated Balance Sheets as of September 30, 2023 and 2022
1
1
Consolidated Financial Statements
1
8/2/23
10-Q
1
Consolidated Statements of Cash Flows for the
2
11/21/23
10-K
1
Consolidated Statements of Cash Flows for the fiscal years ended September 30, 2023, 2022, and 2021
1
1/31/24
10-Q
1
Consolidated Statements of Cash Flows for the three months ended December 31, 2023 and 2022
1
11/21/23
10-K
1
Consolidated Statements of Changes in Stockholders' Equity for the fiscal years ended September 30, 2023, 2022, and 2021
1
1/31/24
10-Q
1
Consolidated Statements of Changes in Stockholders' Equity for the three months ended December 31, 2023 and 2022
1
11/21/23
10-K
1
Consolidated Statements of Comprehensive Income for the fiscal years ended September 30, 2023, 2022, and 2021
1
5/2/23
10-Q
1
Consolidated Statements of Comprehensive Income for the three
1
8/2/23
10-Q
1
Consolidated Statements of Comprehensive Income for the three and
1
1/31/24
10-Q
1
Consolidated Statements of Comprehensive Income for the three months ended December 31, 2023 and 2022
1
11/21/23
10-K
1
Consolidated Statements of Operations for the fiscal years ended September 30, 2023, 2022, and 2021
1
5/2/23
10-Q
1
Consolidated Statements of Operations for the three
1
8/2/23
10-Q
1
Consolidated Statements of Operations for the three and
1
1/31/24
10-Q
1
Consolidated Statements of Operations for the three months ended December 31, 2023 and 2022
1
1
Controls and Procedures
3
1/29/24
DEF 14A
1
Corporate governance
2
1/31/24
10-Q
1
Defaults Upon Senior Securities
3
1/29/24
DEF 14A
1
Delinquent Section 16(a) reports
2
2/6/24
424B2
1
Description of Common Stock and Preferred Stock
4
1
Description of Debt Securities
4
1
Description of Depositary Shares
4
1
Description of Notes
2
1
Description of Purchase Contracts
4
1
Description of Units
4
1
Description of Warrants
4
1/29/24
DEF 14A
1
Director compensation
2
8/7/23
424B7
1
Dividend Policy
2
2/6/24
424B2
1
Documents Incorporated by Reference
4
1/29/24
DEF 14A
1
Election of directors
2
1
Equity compensation plan information
2
1
Executive compensation
2
1
Executive compensation tables
2
6/15/23
11-K
1
Exhibit
1
1/31/24
10-Q
1
Exhibits
5
2/6/24
424B2
1
Experts
4
1/31/24
10-Q
1
Financial Statements (Unaudited)
3
1/29/24
DEF 14A
1
Fiscal 2023 director compensation
2
1
Frequently asked questions about the 2024 Annual Meeting of Shareholders and voting at the meeting
2
11/21/23
10-K
1
Information about our Executive Officers
1
8/2/23
10-Q
1
June 30
1
8/7/23
424B7
1
Legal Matters
2
1/31/24
10-Q
1
Legal Proceedings
3
1
Management's Discussion and Analysis of Financial Condition and Results of Operations
3
5/2/23
10-Q
1
March
1
1/31/24
10-Q
1
Mine Safety Disclosures
3
8/2/23
10-Q
1
Months Ended
2
1
Nine
1
1/31/24
10-Q
1
Notes to Consolidated Financial Statements
4
6/15/23
11-K
1
Notes to Financial Statements
1
1/31/24
10-Q
1
Other Information
5
1/29/24
DEF 14A
1
Our Board of Directors
2
1
Overview
2
11/21/23
10-K
1
Part I
1
1/31/24
10-Q
1
Part I. FINANCIAL INFORMATION
3
11/21/23
10-K
1
Part Ii
1
1/31/24
10-Q
1
Part II. OTHER INFORMATION
3
11/21/23
10-K
1
Part Iii
1
1
Part Iv
1
1/29/24
DEF 14A
1
Pay versus performance
2
2/6/24
424B2
1
Plan of Distribution
4
1/29/24
DEF 14A
1
Pre-approval policies
2
1
Proposed amended and restated certificate of incorporation
2
1
Proposed changes to current amended and restated certificate of incorporation (marked to show changes)
2
1
Proxy statement summary
2
1/31/24
10-Q
1
Quantitative and Qualitative Disclosures About Market Risk
3
1/29/24
DEF 14A
1
Ratification of the appointment of Ernst & Young LLP as Cencora's Independent Registered Public Accounting Firm for Fiscal 2024
2
11/21/23
10-K
1
Report of Ernst & Young LLP, Independent Registered Public Accounting Firm
1
1
Report of Independent Registered Public Accounting Firm
2
1/29/24
DEF 14A
1
Report of the Audit Committee
2
1
Report of the Compensation Committee
2
1
Requirements for submission of proxy proposals, nomination of directors and other business of shareholders
2
2/6/24
424B2
1
Risk Factors
7
1
S-1
4
8/7/23
424B7
1
S-10
2
2/6/24
424B2
1
S-11
2
8/7/23
424B7
1
S-12
2
1
S-15
2
1
S-16
2
1
S-18
2
1
S-22
2
1
S-24
2
2/6/24
424B2
1
S-28
2
8/7/23
424B7
1
S-3
2
1
S-31
2
2/6/24
424B2
1
S-33
2
1
S-4
2
1
S-40
2
8/7/23
424B7
1
S-5
2
2/6/24
424B2
1
S-8
2
1
S-9
2
1
S-ii
2
1
S-iii
2
11/21/23
10-K
1
Schedule II -- Valuation and Qualifying Accounts
1
6/15/23
11-K
1
Schedule of Assets (Held at End of Year)
1
1/29/24
DEF 14A
1
Security ownership of certain beneficial owners, officers and directors
2
1
Selection and engagement of audit firm
2
8/7/23
424B7
1
Selling Stockholder
2
1/29/24
DEF 14A
1
Shareholder proposal
2
6/15/23
11-K
1
Signature
1
1/31/24
10-Q
1
Signatures
4
5/2/23
10-Q
1
Six
1
6/15/23
11-K
1
Statement of Changes in Net Assets Available for Benefits
1
1
Statements of Net Assets Available for Benefits
1
1/29/24
DEF 14A
1
Stock ownership information
2
2/6/24
424B2
1
Summary
2
8/7/23
424B7
1
Summary of the Offering
2
1/29/24
DEF 14A
1
Supplemental information: GAAP to non-GAAP reconciliation
2
2/6/24
424B2
1
Table of Contents
11
1
U.S. Federal Income Tax Consequences
2
1
Underwriting
4
1/31/24
10-Q
1
Unregistered Sales of Equity Securities and Use of Proceeds
3
2/6/24
424B2
1
Use of Proceeds
4
1
Validity of Securities
4
11/21/23
10-K
1
Valuation and Qualifying Accounts
1
2/6/24
424B2
1
Where You Can Find More Information
4
11/21/23
10-K
1
1. Business
1
1
10. Directors, Executive Officers, and Corporate Governance
1
1
11. Executive Compensation
1
1
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
1
1
13. Certain Relationships and Related Transactions, and Director Independence
1
1
14. Principal Accounting Fees and Services
1
1
15. Exhibits, Financial Statement Schedules
1
1
16. Form 10-K Summary
1
1
1A. Risk Factors
1
1
1B. Unresolved Staff Comments
1
1
2. Properties
1
8/2/23
10-Q
1
2023 and 2022
1
1
2023 and September 30, 2022
1
11/21/23
10-K
1
3. Legal Proceedings
1
5/2/23
10-Q
1
31, 202
1
11/21/23
10-K
1
4. Mine Safety Disclosures
1
1
5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
1
1
6. [Reserved
1
1
7. Management's Discussion and Analysis of Financial Condition and Results of Operations
1
1
7A. Quantitative and Qualitative Disclosures About Market Risk
1
1
8. Financial Statements and Supplementary Data
1
1
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
1
1
9A. Controls and Procedures
1
1
9B. Other Information
1
1
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
1
↑
Top
Copyright © 2024
Fran Finnegan & Company LLC
– All Rights Reserved.
About
—
Privacy
—
Redactions
—
Help
— Wed., May 1, 10:51:58.
2am ET